595 related articles for article (PubMed ID: 32081200)
1. The strategies of targeting the NLRP3 inflammasome to treat inflammatory diseases.
Jiang H; Gong T; Zhou R
Adv Immunol; 2020; 145():55-93. PubMed ID: 32081200
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic regulation of the NLRP3 inflammasome in chronic inflammatory diseases.
Seok JK; Kang HC; Cho YY; Lee HS; Lee JY
Arch Pharm Res; 2021 Jan; 44(1):16-35. PubMed ID: 33534121
[TBL] [Abstract][Full Text] [Related]
3. NLRP3 Inflammasome-A Key Player in Antiviral Responses.
Zhao C; Zhao W
Front Immunol; 2020; 11():211. PubMed ID: 32133002
[TBL] [Abstract][Full Text] [Related]
4. Exogenous nanoparticles and endogenous crystalline molecules as danger signals for the NLRP3 inflammasomes.
Shirasuna K; Karasawa T; Takahashi M
J Cell Physiol; 2019 May; 234(5):5436-5450. PubMed ID: 30370619
[TBL] [Abstract][Full Text] [Related]
5. Cellular Models and Assays to Study NLRP3 Inflammasome Biology.
Zito G; Buscetta M; Cimino M; Dino P; Bucchieri F; Cipollina C
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32560261
[TBL] [Abstract][Full Text] [Related]
6. Molecular mechanisms regulating NLRP3 inflammasome activation.
Jo EK; Kim JK; Shin DM; Sasakawa C
Cell Mol Immunol; 2016 Mar; 13(2):148-59. PubMed ID: 26549800
[TBL] [Abstract][Full Text] [Related]
7. Multifactorial functions of the inflammasome component NLRP3 in pathogenesis of chronic kidney diseases.
Mulay SR
Kidney Int; 2019 Jul; 96(1):58-66. PubMed ID: 30922667
[TBL] [Abstract][Full Text] [Related]
8. Current status of terpenoids as inflammasome inhibitors.
Hortelano S; González-Cofrade L; Cuadrado I; de Las Heras B
Biochem Pharmacol; 2020 Feb; 172():113739. PubMed ID: 31786260
[TBL] [Abstract][Full Text] [Related]
9. Inhibiting NLRP3 Inflammasome Activity in Acute Myocardial Infarction: A Review of Pharmacologic Agents and Clinical Outcomes.
Buckley LF; Libby P
J Cardiovasc Pharmacol; 2019 Oct; 74(4):297-305. PubMed ID: 31356538
[TBL] [Abstract][Full Text] [Related]
10. NLRP3 Inflammasome in Acute Myocardial Infarction.
Mauro AG; Bonaventura A; Mezzaroma E; Quader M; Toldo S
J Cardiovasc Pharmacol; 2019 Sep; 74(3):175-187. PubMed ID: 31356555
[TBL] [Abstract][Full Text] [Related]
11. Role of NLRP3 inflammasome in inflammatory bowel diseases.
Tourkochristou E; Aggeletopoulou I; Konstantakis C; Triantos C
World J Gastroenterol; 2019 Sep; 25(33):4796-4804. PubMed ID: 31543674
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic Targeting of NLRP3 Inflammasomes by Natural Products and Pharmaceuticals: A Novel Mechanistic Approach for Inflammatory Diseases.
Jahan S; Kumar D; Chaturvedi S; Rashid M; Wahajuddin M; Khan YA; Goyal SN; Patil CR; Mohanraj R; Subramanya S; Ojha S
Curr Med Chem; 2017; 24(16):1645-1670. PubMed ID: 28245768
[TBL] [Abstract][Full Text] [Related]
13. Negative regulators and their mechanisms in NLRP3 inflammasome activation and signaling.
Kim JK; Jin HS; Suh HW; Jo EK
Immunol Cell Biol; 2017 Aug; 95(7):584-592. PubMed ID: 28356568
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease.
Abbate A; Toldo S; Marchetti C; Kron J; Van Tassell BW; Dinarello CA
Circ Res; 2020 Apr; 126(9):1260-1280. PubMed ID: 32324502
[TBL] [Abstract][Full Text] [Related]
15. Phytochemical inhibitors of the NLRP3 inflammasome for the treatment of inflammatory diseases.
Özenver N; Efferth T
Pharmacol Res; 2021 Aug; 170():105710. PubMed ID: 34089866
[TBL] [Abstract][Full Text] [Related]
16. The NLRP3 Inflammasome as a Pharmacological Target.
Marchetti C
J Cardiovasc Pharmacol; 2019 Oct; 74(4):285-296. PubMed ID: 31335445
[TBL] [Abstract][Full Text] [Related]
17. The NLRP3 inflammasome - interleukin 1 pathway as a therapeutic target in gout.
Szekanecz Z; Szamosi S; Kovács GE; Kocsis E; Benkő S
Arch Biochem Biophys; 2019 Jul; 670():82-93. PubMed ID: 30710503
[TBL] [Abstract][Full Text] [Related]
18. NEK7: a potential therapy target for NLRP3-related diseases.
Liu G; Chen X; Wang Q; Yuan L
Biosci Trends; 2020 May; 14(2):74-82. PubMed ID: 32295992
[TBL] [Abstract][Full Text] [Related]
19. Targeting NLRP3 (Nucleotide-Binding Domain, Leucine-Rich-Containing Family, Pyrin Domain-Containing-3) Inflammasome in Cardiovascular Disorders.
Wang Z; Hu W; Lu C; Ma Z; Jiang S; Gu C; Acuña-Castroviejo D; Yang Y
Arterioscler Thromb Vasc Biol; 2018 Dec; 38(12):2765-2779. PubMed ID: 30571177
[TBL] [Abstract][Full Text] [Related]
20. NLRP3 inflammasome as a key driver of vascular disease.
Takahashi M
Cardiovasc Res; 2022 Jan; 118(2):372-385. PubMed ID: 33483732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
